Stockreport

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases [Yahoo! Finance]

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF -Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of ZL-1503, together with a favorable preclinical safety profile, su [Read more]